Catalog No.
Product Name
Application
Product Information
Citations
-
GLP-1R Agonist Isomer
(1R)-GLP-1 receptor agonist 12 is an isomer targeting the GLP-1 receptor (GLP-1R). It exhibits significant agonistic activity, which can stimulate insulin secretion and enhance β-cell function. This compound is particularly relevant in diabetes research and the study of metabolic disorders, making it a valuable tool for exploring therapeutic strategies in glucose homeostasis and appetite regulation. -
GLP-1R Agonist
GLP-1R agonist 12 is a selective agonist for glucagon-like peptide-1 receptors (GLP-1R), which are integral to glucose metabolism and insulin secretion. This compound promotes insulin release and inhibits glucagon secretion, making it a valuable tool in diabetes research. Its activity may aid in the exploration of therapeutic strategies for metabolic disorders and related conditions. -
GLP Receptor Agonist
Bofanglutide is an analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist, exhibiting an EC50 of 0.677 nM. This compound demonstrates significant efficacy in ameliorating type 2 diabetes by enhancing insulin secretion, suppressing glucagon release, and promoting β-cell proliferation. Bofanglutide is a valuable tool for diabetes research and therapeutic development targeting metabolic disorders. -
GLP-1 Receptor Agonist
GLP-1 receptor agonist 12 is a potent agonist targeting the glucagon-like peptide-1 (GLP-1) receptor. This compound enhances insulin secretion and exhibits glucose-dependent effects, making it instrumental in diabetes research. Its mechanism of action provides valuable insights into the regulation of glucose homeostasis and potential therapeutic strategies for metabolic disorders. -
Liraglutide Side Chain
Pal-Glu(OSu)-OH is a side chain of Liraglutide, which functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. This compound is pivotal in research relating to type 2 diabetes mellitus, facilitating the study of metabolic regulation and therapeutic strategies targeting GLP-1 pathways. Its utilization aids in advancing knowledge in diabetes treatment and obesity research. -
GLP-1R Inhibitor
GLP-1 receptor agonist 13 is a selective agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 76 nM. This compound plays a significant role in enhancing glucose-dependent insulin secretion, thereby influencing metabolic processes. It is particularly useful in research applications focused on diabetes, obesity, and related metabolic disorders. -
GLP-1 Antagonist
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that plays a critical role in the study of hypoglycemia. By inhibiting GLP-1 activity, Imapextide provides insights into glucose homeostasis and insulin secretion regulation. It is a valuable tool for researchers investigating metabolic disorders and the physiological effects of GLP-1 signaling. -
GLP-1 Analog
HAEGTFTSDVSSYLE is a GLP-1 analog designed to interact with GLP-1 receptors, mimicking the activity of endogenous glucagon-like peptide-1. This polypeptide exhibits key biological activities including the stimulation of insulin secretion and the inhibition of glucagon release, thereby regulating glucose homeostasis. HAEGTFTSDVSSYLE is utilized in research applications related to diabetes treatment, metabolic disorders, and obesity studies. -
Anti-GLP-1 receptor Antibody
Efmedaglutide alfa is an anti-GLP-1 receptor antibody designed to interact specifically with the glucagon-like peptide-1 receptor. This fusion protein exhibits potent biological activity, promoting insulin secretion and inhibiting glucagon release, making it a useful tool in studies related to diabetes and metabolic disorders. Its application in research can aid in understanding the role of GLP-1 signaling in glucose homeostasis and potential therapeutic interventions for related diseases. -
Anti-GLP-1 receptor Antibody
Efsubaglutide alfa is an anti-GLP-1 receptor antibody designed to target and inhibit the GLP-1 receptor, a key regulator of glucose metabolism and insulin secretion. This fusion protein exhibits potent biological activity in modulating glucose homeostasis and is primarily utilized in diabetes research. Its application extends to studies focused on the therapeutic potential for metabolic disorders and obesity management. -
GIPR/GLP-1R Agonist
Zantrutide is an agonist of the glucagon, gastric inhibitory polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). It exhibits significant biological activity in the modulation of glucose metabolism and insulin secretion. This compound is valuable for research applications targeting metabolic diseases, particularly in the exploration of obesity and type 2 diabetes treatment strategies. -
GLP-1R PAM
(S)-V-0219 is a selective positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). It induces calcium flux in HEK293 cells expressing human GLP-1R, enhancing receptor activity. In vivo studies demonstrate that (S)-V-0219 is orally bioavailable, effectively reducing hyperglycemia in murine models while also suppressing feeding behavior in fasting conditions. This compound presents valuable applications in diabetes research and appetite regulation studies. -
GLP-1R Agonist
GLP-1R Agonist 18 is a potent agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.044 nM. This compound enhances insulin secretion in response to glucose, making it a valuable tool for research in diabetes and metabolic disorders. Its high affinity for GLP-1R positions it as a significant candidate for investigating therapeutic strategies targeting glucose homeostasis and appetite regulation. -
GLP-1 Analogue
Vurolenatide is a long-acting GLP-1 analogue that targets the glucagon-like peptide-1 receptor. It exhibits significant biological activity by enhancing insulin secretion, promoting satiety, and reducing gastric emptying, making it relevant for metabolic studies. Vurolenatide is particularly useful in research applications focusing on short bowel syndrome and disorders related to glucose metabolism. -
GLP-1R Agonist
GLP-1R agonist 15 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound plays a significant role in enhancing insulin secretion, inhibiting glucagon release, and promoting glucose-dependent insulin action. It is primarily utilized in research focused on metabolic disorders, including diabetes and obesity, and may aid in the development of novel therapeutic strategies targeting GLP-1R pathways. -
GLP Receptor Agonist
GLP-1R agonist 21 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting a potent binding affinity with an EC50 of 0.0104 nM. This compound enhances insulin secretion, promotes glucose-dependent insulin release, and plays a critical role in glucose homeostasis. It is primarily utilized in research related to metabolic disorders, diabetes, and obesity, providing valuable insights into therapeutic strategies targeting GLP-1R pathways. -
GLP-1R Agonist
Linvixdutide is a potent GLP-1 receptor (GLP-1R) agonist known for its anti-obesity effects. By stimulating the GLP-1 pathway, it promotes insulin secretion, reduces glucagon release, and enhances satiety, making it a valuable tool in obesity research. This compound may also have applications in the study of metabolic disorders and diabetes management. -
GLP Receptor Agonist
GLP-1 receptor agonist 15 selectively targets the GLP-1 receptor with an EC50 of 0.74 nM, demonstrating potent activity. This compound has an IC50 value of 10.1 μM for the hERG potassium ion channel, indicating a suitable safety profile. GLP-1 receptor agonist 15 is primarily utilized in diabetes research, providing valuable insights into glucose metabolism and insulin signaling pathways. -
GLP-1R Agonist
GLP-1R agonist 19 is a potent and selective agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound demonstrates excellent plasma stability and liver microsomal stability, making it suitable for in vitro and in vivo studies. Additionally, it exhibits low hERG toxicity, ensuring a reduced risk of off-target effects. Research applications include investigations into glucose homeostasis, metabolic disorders, and potential therapeutics for type 2 diabetes. -
GLP Receptor Agonist
GLP-1R agonist 20 (Compound I-132) is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 0.0162 nM. This compound plays a crucial role in enhancing insulin secretion and promoting glucose homeostasis. It is valuable for research applications focused on metabolic disorders such as type 2 diabetes and obesity. -
GLP-1R Agonist
GLP-1R agonist 27 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), demonstrating significant oral bioactivity. It enhances cyclic adenosine monophosphate (cAMP) accumulation, which is associated with reduced blood glucose levels and decreased food intake. This compound is instrumental in research related to obesity and type 2 diabetes mellitus (T2DM), offering potential insights into therapeutic approaches for metabolic disorders. -
GLP-1R PAM
(R)-V-0219 is a positive allosteric modulator of the GLP-1 receptor (GLP-1R), functioning through enhanced receptor activation. It promotes calcium flux in human embryonic kidney (HEK) cells expressing hGLP-1R, indicating its role in metabolic regulation. This compound is particularly relevant for research focused on type 2 diabetes and obesity, allowing scientists to explore the therapeutic potentials of GLP-1R modulation. -
GLP-1R Agonist
Zabopegdutide is a selective agonist of the glucagon-like peptide 1 receptor (GLP-1R). It exhibits significant biological activity in the modulation of glucose homeostasis and appetite regulation, making it a valuable tool for obesity research. This compound can facilitate studies aimed at understanding GLP-1R signaling pathways and their implications in metabolic disorders. -
GLP-1R Agonist
GLP-1R agonist 16 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.15 nM. This compound is known to enhance insulin secretion and promote glucose-dependent insulin release, making it a valuable tool for diabetes research. GLP-1R agonist 16 is utilized in studies focused on metabolic pathways, therapeutic development for Type 2 diabetes, and potential cardiovascular effects related to GLP-1 signaling. -
GLP-1 Receptor Agonist
GLP-1R Agonist 14 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0-20 nM for human GLP-1 receptors. This compound stimulates insulin secretion and inhibits glucagon release, making it a valuable tool for studying glucose metabolism and diabetes-related research. Its strong activity at the GLP-1R positions it as an essential reagent for investigating potential therapeutic strategies in metabolic disorders. -
GLP Receptor Agonist
GLP-1R agonist 41 is a potent agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.0187 nM. This compound actively stimulates GLP-1 signaling pathways, playing a significant role in glucose homeostasis and insulin secretion. It is primarily used in research focused on metabolic disorders such as diabetes and obesity, as well as in the investigation of potential therapeutic interventions targeting GLP-1R. -
GLP Receptor Agonist
GLP-1R agonist 22 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 0.0165 nM. This compound stimulates insulin secretion and enhances glucose homeostasis, making it a valuable tool for research in diabetes and metabolic disorders. Its specific action on GLP-1R allows for exploration of therapeutic applications in obesity and related conditions. -
GLP-1 Secretagogue
JWU-A021 is a GLP-1 secretagogue that functions by activating the TRPA1 cation channel, resulting in a calcium ion influx and increased intracellular calcium levels in enteroendocrine cells and TRPA1-transfected cells. This activation subsequently stimulates the secretion of glucagon-like peptide-1 (GLP-1) from intestinal enteroendocrine and L cells. JWU-A021 is valuable for research in the context of type 2 diabetes, offering insights into GLP-1 modulation and its potential therapeutic implications. -
GLP-1 Agonist
GLP-1R agonist 33 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R). It exhibits significant bioactivity in stimulating insulin secretion and suppressing glucagon release, making it a valuable tool for investigating metabolic disorders. This compound is particularly applicable in research focused on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). -
GIP/GLP-1 Receptor Agonist
Acmopatide is a dual-acting agonist of the GIP and GLP-1 receptors. This compound exhibits significant biological activity in enhancing insulin secretion and regulating glucose homeostasis, making it a valuable tool in anti-diabetic research. Its unique mechanism of action supports investigations into novel therapeutic approaches for diabetes management. -
GLP-1R Agonist
GLP-1R Agonist 34 is a small molecule that functions as an agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to effective reductions in blood glucose levels. GLP-1R Agonist 34 is a valuable tool for research into metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). -
GLP-1R Agonist
GLP-1R agonist 35 selectively targets the glucagon-like peptide-1 receptor (GLP-1R) with an EC50 of 0-10 nM, demonstrating potent agonistic activity. This compound is valuable for research applications focused on diabetes and obesity, facilitating the exploration of GLP-1R modulation in metabolic disorders and potential therapeutic interventions. -
GLP-1R/GIPR Agonist
GLP-1R/GIPR agonist-2 is a selective agonist targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). It effectively enhances GIP(1-42)-induced intracellular cAMP production in human GIPR-expressing cells. This compound is valuable for research into type II diabetes mellitus, contributing to the understanding of insulin secretion and glucose homeostasis. -
GLP-1R Agonist
(Asp28)-Exenatide is a potent GLP-1 receptor agonist known for its role in glucose homeostasis. This compound is a degradation product of exenatide and retains significant biological activity, making it valuable for research applications related to diabetes and metabolism. (Asp28)-Exenatide may provide insights into the pharmacological mechanisms of GLP-1R stimulation and its effects on insulin secretion and appetite regulation. -
GLP-1 Receptor Agonist
Vensemaglutide is a GLP-1 receptor agonist that enhances insulin secretion and inhibits glucagon release in a glucose-dependent manner. This compound demonstrates significant biological activity in regulating blood glucose levels and promoting weight loss, making it useful for research in diabetes and other metabolic disorders. Its mechanism of action supports investigations into therapeutic strategies for managing conditions related to glucose homeostasis. -
GLP-1R Agonist
Taspoglutide acetate is a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting a Ki value of 1.1 nM. This compound effectively stimulates cAMP accumulation in CHO-K1 cells expressing human GLP-1R, with an EC50 of 0.06 nM. In vivo studies demonstrate that Taspoglutide acetate significantly reduces blood glucose levels and elevates insulin levels in Zucker diabetic obese rats. Additionally, it has been shown to lower gastric inhibitory polypeptide (GIP) levels, plasma triglycerides, and body weight in this model, highlighting its potential for metabolic research and diabetes treatment. -
GLP-1R/GIPR Agonist
Poterepatide is a long-acting dual agonist of the GLP-1 receptor (GLP-1R) and glucose-dependent insulinotropic peptide receptor (GIPR). It demonstrates significant activity at both receptor sites, making it a valuable tool in the investigation of metabolic disorders. Poterepatide is primarily utilized in research focused on obesity and type 2 diabetes, offering insights into potential therapeutic strategies for these conditions. -
GLP-1 Receptor Agonist
Zovaglutide is a long-acting GLP-1 receptor agonist that enhances albumin binding capacity through dual fatty acid chain modification. It mediates metabolic effects via central and peripheral GLP-1 pathways, promoting satiety, reducing caloric intake, and enhancing glucose-dependent insulin secretion, without affecting GIP or glucagon receptors. This compound is well-suited for research applications related to type 2 diabetes and obesity. -
GLP-1R Agonist
Anvoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that plays a significant role in the regulation of glucose metabolism and appetite control. This compound exhibits potent antidiabetic and anti-obesity properties, making it a valuable tool for research in metabolic disorders. Its ability to enhance insulin secretion and reduce glucagon levels supports its application in studies focused on type 2 diabetes and weight management interventions. -
GLP-1R Agonist
GLP-1R modulator-1 is a potent selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), acting primarily through G-protein coupled signaling pathways. This compound elevates intracellular cAMP levels, facilitating insulin secretion, delaying gastric emptying, and suppressing appetite. GLP-1R modulator-1 is valuable for research in type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). -
GLP-1 Agonist
Liraglutide acetate is an acetate derivative of Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily utilized in the management of type 2 diabetes by enhancing insulin secretion, suppressing glucagon release, and promoting glucose-dependent regulation of blood sugar levels. Research applications include studies on metabolic disorders, appetite regulation, and cardiovascular effects related to GLP-1 signaling. -
GLP-1R Agonist
GLP-1R-agonist-43 is a potent GLP-1 receptor agonist with an EC50 of 2.68 nM, demonstrating significant biological activity. This compound is primarily utilized in research focused on non-insulin-dependent diabetes mellitus (type 2 diabetes) and obesity. Its capacity to stimulate the GLP-1 receptor makes it a valuable tool for investigating metabolic disorders and potential therapeutic interventions. -
GLP-1R Agonist
GLP-1R agonist 36 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting activity through receptor activation. This compound plays a crucial role in regulating glucose homeostasis and appetite control, making it a valuable tool in diabetes and obesity research. Its multiple isomers allow for comprehensive studies on receptor interaction and therapeutic potential. -
GLP Receptor Agonist
GLP-1R agonist 42 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.0122 nM. This compound effectively stimulates insulin secretion and modulates glucagon release, making it relevant for diabetes research. Its application in metabolic studies provides insights into glucose homeostasis and potential therapeutic targets for metabolic disorders. -
GLP-1 Receptor Agonist
Berobenatide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist, which stimulates insulin secretion and inhibits glucagon release in a glucose-dependent manner. This compound plays a crucial role in enhancing glucose homeostasis and promoting weight loss. Berobenatide is primarily utilized in research related to diabetes management and obesity treatment. -
GLP-1R Agonist
GLP-1R agonist 23 is a potent agonist of the GLP-1 receptor, exhibiting an EC50 of 0.056 nM. This compound plays a critical role in enhancing insulin secretion and glucose homeostasis, making it valuable for diabetes research and therapeutic applications. Its high affinity and specificity for GLP-1R support studies aimed at understanding glucoregulatory mechanisms and developing potential treatments for metabolic disorders. -
GLP-1 Receptor Agonist
GLP-1R Agonist 13 is a selective agonist of the GLP-1 receptor, which plays a crucial role in glucose metabolism and appetite regulation. This compound exhibits potent biological activity by enhancing insulin secretion and inhibiting glucagon release, making it a valuable tool for diabetes research. Its application extends to studying metabolic disorders and evaluating potential therapeutic strategies for conditions such as type 2 diabetes and obesity. -
Glucagon Peptide
(Asp28)-Glucagon (1-29) is a modified form of the glucagon peptide, where aspartic acid (Asp) has been introduced at position 28 to enhance its aqueous solubility in physiological pH buffers. This structural optimization preserves the biological activity characteristic of glucagon. It serves as a valuable reagent for research applications that investigate glucagon's role in glucose metabolism, diabetes, and other metabolic disorders in human, rat, and porcine models. -
GLP-1 Agonist
GLP-1 Receptor Agonist 16 is a potent agonist of the GLP-1 receptor, primarily involved in regulating glucose metabolism and appetite. This compound demonstrates significant biological activity in modulating insulin secretion and promoting weight loss. It is particularly valuable in research focused on diabetes, obesity, and nonalcoholic steatohepatitis-related conditions. -
GLP-1R Agonist
GLP-1R agonist 30 is a highly selective and orally active agonist of the glucagon-like peptide-1 receptor (GLP-1R), demonstrating an EC50 of 0.048 nM. It displays significant selectivity with EC50 values greater than 20 μM for GLP-2 receptor, GIP receptor, and glucagon receptor. This compound enhances cAMP signaling while minimizing hERG inhibition, indicating favorable safety profiles. It effectively improves glucose tolerance and promotes insulin secretion in B-hGLP1R knock-in mouse models, making it a valuable tool for research applications in diabetes and metabolic disorders.
